SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Jun 15, 2012

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: June 15, 2012 · CIK: 0001368514 · Accession: 0001193805-12-001053

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 000-52120

Referenced dates: May 9, 2012

Date

June 15, 2012

Author

/s/ Brian Lenz

Form

CORRESP

Company

ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance ADMA Biologics, Inc. Amendment No. 2 to Form 8-K Filed April 24, 2012 File No. 000-52120

Dear Messrs. Dobbie and Brown:

By letter dated May 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). As discussed between Mr. Brown and Roland Chase, of our counsel SNR Denton US LLP, the Company currently expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing, on or before June 22, 2012.

If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at SNR Denton US LLP at (973) 912-7100.

Sincerely,
/s/ Brian Lenz

Show Raw Text

CORRESP
1
filename1.htm

    Unassociated Document

[ADMA LETTERHEAD]

June 15, 2012

VIA EDGAR

Mr. Justin Dobbie

Mr. John Dana Brown

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC  20549

Re:

ADMA Biologics, Inc.

Amendment No. 2 to Form 8-K

Filed April 24, 2012

File No. 000-52120

Dear Messrs. Dobbie and Brown:

By letter dated May 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”).  As discussed between Mr. Brown and Roland Chase, of our counsel SNR Denton US LLP, the Company currently expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing, on or before June 22, 2012.

If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at SNR Denton US LLP at (973) 912-7100.

Sincerely,

/s/ Brian Lenz

Brian Lenz

Chief Financial Officer

Cc:

Adam S. Grossman

President and Chief Executive Officer

SecProbe.io